We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?
Read MoreHide Full Article
Key Takeaways
UHS' Q3 earnings are projected to decline 6.3% year over year, despite an expected 5.1% revenue increase.
Higher admissions may lift acute care and behavioral health revenues by 4.6% and 4.9%, respectively.
UHS faces nearly 6% higher operating expenses, driven by rising wages, benefits and supply costs.
Hospital operator Universal Health Services, Inc. (UHS - Free Report) is set to report third-quarter 2026 results on Oct. 27, 2026, after the closing bell. The Zacks Consensus Estimate for earnings is currently pegged at $5.33 per share on revenues of $4.73 billion.
The third-quarter earnings estimate has witnessed three downward revisions and no upward revision over the past 60 days. The bottom-line projection indicates a year-over-year decrease of 6.3%. The Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 5.1%.
Image Source: Zacks Investment Research
For full-year 2026, the Zacks Consensus Estimate for Universal Health’s revenues is pegged at $18.63 billion, implying a rise of 7.3% year over year. The consensus mark for full-year EPS is pegged at $22.87, implying growth of 5.2% on a year-over-year basis.
Universal Health beat on earnings in three of the last four quarters and missed once, with the average surprise being 8.3%. This is depicted in the figure below.
Universal Health Services, Inc. Price and EPS Surprise
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
UHS currently has an Earnings ESP of -0.60% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping UHS’ Q3 Results?
Universal Health's performance likely benefited from higher patient days and admissions in both its Acute Care Hospital Services and Behavioral Health Care Services segments.
The Zacks Consensus Estimate for net revenues in the Acute Care Hospital Services segment is pegged at almost $2.75 billion, indicating 4.6% year-over-year growth. The consensus mark for the unit’s same-facility adjusted admissions indicates 3.4% growth from the prior-year quarter’s level.
The Zacks Consensus Estimate for net revenues in the Behavioral Health Care Services segment is pegged at $1.95 billion, indicating a 4.9% increase from the prior-year quarter’s figure. The consensus estimate for the unit’s admissions indicates a year-over-year increase of 2.6%.
The Zacks Consensus Estimate for operating income from Acute Care Hospital Services indicates a 9.6% year-over-year decline, while the same from Behavioral Health Care Services suggests a 1.1% increase.
The positives are likely to have been partially offset by rising total operating expenses by nearly 6%, due to higher salaries, wages and benefits, as well as increased costs for supplies in the third quarter, making an earnings beat uncertain. We anticipate salaries, wages and benefits to increase nearly 4.3% year over year, while other operating costs are expected to escalate 7.7%.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Universal Health, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
The Zacks Consensus Estimate for Phibro’s bottom line for the third quarter suggests 8.2% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 18.4%. PAHC’s revenues for the to-be-reported quarter are pegged at $ 378.5 million, suggesting a 4% increase from the year-ago period.
ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +22.43% and a Zacks Rank #2 at present.
The Zacks Consensus Estimate for ProMIS’ bottom line for the third quarter indicates a loss of $1.26 per share, reflecting a 79% year-over-year improvement. PMN has witnessed one upward revision and no downward revisions over the past 60 days.
Illumina, Inc. (ILMN - Free Report) has an Earnings ESP of +9.16% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for Illumina’s third-quarter bottom line suggests 3% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 9.7%. ILMN’s revenues for the to-be-reported quarter are pegged at $1.14 billion, indicating a 5% increase from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?
Key Takeaways
Hospital operator Universal Health Services, Inc. (UHS - Free Report) is set to report third-quarter 2026 results on Oct. 27, 2026, after the closing bell. The Zacks Consensus Estimate for earnings is currently pegged at $5.33 per share on revenues of $4.73 billion.
The third-quarter earnings estimate has witnessed three downward revisions and no upward revision over the past 60 days. The bottom-line projection indicates a year-over-year decrease of 6.3%. The Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 5.1%.
Image Source: Zacks Investment Research
For full-year 2026, the Zacks Consensus Estimate for Universal Health’s revenues is pegged at $18.63 billion, implying a rise of 7.3% year over year. The consensus mark for full-year EPS is pegged at $22.87, implying growth of 5.2% on a year-over-year basis.
Universal Health beat on earnings in three of the last four quarters and missed once, with the average surprise being 8.3%. This is depicted in the figure below.
Universal Health Services, Inc. Price and EPS Surprise
Universal Health Services, Inc. price-eps-surprise | Universal Health Services, Inc. Quote
Q3 Earnings Whispers for UHS
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
UHS currently has an Earnings ESP of -0.60% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping UHS’ Q3 Results?
Universal Health's performance likely benefited from higher patient days and admissions in both its Acute Care Hospital Services and Behavioral Health Care Services segments.
The Zacks Consensus Estimate for net revenues in the Acute Care Hospital Services segment is pegged at almost $2.75 billion, indicating 4.6% year-over-year growth. The consensus mark for the unit’s same-facility adjusted admissions indicates 3.4% growth from the prior-year quarter’s level.
The Zacks Consensus Estimate for net revenues in the Behavioral Health Care Services segment is pegged at $1.95 billion, indicating a 4.9% increase from the prior-year quarter’s figure. The consensus estimate for the unit’s admissions indicates a year-over-year increase of 2.6%.
The Zacks Consensus Estimate for operating income from Acute Care Hospital Services indicates a 9.6% year-over-year decline, while the same from Behavioral Health Care Services suggests a 1.1% increase.
The positives are likely to have been partially offset by rising total operating expenses by nearly 6%, due to higher salaries, wages and benefits, as well as increased costs for supplies in the third quarter, making an earnings beat uncertain. We anticipate salaries, wages and benefits to increase nearly 4.3% year over year, while other operating costs are expected to escalate 7.7%.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Universal Health, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Phibro Animal Health Corporation (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Phibro’s bottom line for the third quarter suggests 8.2% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 18.4%. PAHC’s revenues for the to-be-reported quarter are pegged at $ 378.5 million, suggesting a 4% increase from the year-ago period.
ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +22.43% and a Zacks Rank #2 at present.
The Zacks Consensus Estimate for ProMIS’ bottom line for the third quarter indicates a loss of $1.26 per share, reflecting a 79% year-over-year improvement. PMN has witnessed one upward revision and no downward revisions over the past 60 days.
Illumina, Inc. (ILMN - Free Report) has an Earnings ESP of +9.16% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for Illumina’s third-quarter bottom line suggests 3% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 9.7%. ILMN’s revenues for the to-be-reported quarter are pegged at $1.14 billion, indicating a 5% increase from the year-ago period’s level.